Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients

Journal of the American Academy of Dermatology

Volumn 51, Issue 1, 2004, Pages 126-131

  Sansbury, Julia C ^a   Cocuroccia, Barbara ^b   Jorizzo, Joseph L ^b   Gubinelli, Emanuela ^b   Gisondi, Paolo ^b   Girolomoni, Giampiero ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETRETIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ANAMNESIS; ARTICLE; ASTHENIA; CASE REPORT; CAUSE OF DEATH; CLINICAL EXAMINATION; CLINICAL FEATURE; CONSTIPATION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; HEART INFARCTION; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; PARAPROTEINEMIA; PRIORITY JOURNAL; RECALCITRANT SCLEROMYXEDEMA; SCLEROMYXEDEMA; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; TREATMENT OUTCOME;

AGED; FEMALE; HUMANS; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; MYXEDEMA; PARAPROTEINEMIAS; SCLERODERMA, SYSTEMIC; THALIDOMIDE;

EID: 3042823274     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.01.058     Document Type: Article

References (23)

1. Rongioletti F., Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 44:2001;273-281
2. Dinneen A.M., Dicken C.H. Scleromyxedema. J Am Acad Dermatol. 33:1995;37-43
3. Pomann J.J., Rudner E.J. Scleromyxedema revisited. Int J Dermatol. 42:2003;31-35
4. Jackson E.M., English J.C. III. Diffuse cutaneous mucinoses. Dermatol Clin. 20:2002;493-501
5. Lister R.K., Jolles S., Whitteker S., Black C., Forgacs I., Cramp M., et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIG). J Am Acad Dermatol. 43:2000;403-408
6. Stephens C.J., McKee P.H., Black M.M. The dermal mucinoses. Adv Dermatol. 8:1993;201-206
7. Gonzales J., Palangio M., Schwartz J., Klainer A.S., Bisaccia E. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol. 42:2000;927-928
8. Rongioletti F., Rebora A. Cutaneous mucinosis: microscopic criteria for diagnosis. Am J Dermatopathol. 23:2001;257-267
9. Godby A., Bergstresser P.R., Chaker B., Pandya A.G. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 38:1998;289-294
10. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1999;1565-1571
11. Leleu X., Magro L., Fawaz A., Bauters F., Facon T., Agha I.Y. Efficacy of low dose of thalidomide in advanced multiple myeloma. Blood. 100:2002;1519-1520
12. Atra E., Sato E.I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 11:1993;487-493
13. Tsirigotis P., Venetis E., Rontogianni D., Dernoulas J., Kontopidou F., Apostolidis P. Thalidomide in the treatment of myelodysplastic syndrome with fibrosis. Leuk Res. 26:2002;965-966
14. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 99:1995;160-167
15. Von Moos R., Stolz R., Cerny T., Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly. 133:2003;77-87
16. Richardson P., Hideshima T., Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 53:2002;629-657
17. Lu K.Q., Gaspari A.A. Medical use of thalidomide: past, present and future. Dermatol Found. 36:2002;1-12
18. Bastuji-Garin S., Ochonisky S., Bouche P., Ghrardi R.K., Duguet C., Djerradine Z., et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 119:2002;1020-1026
19. Hall V.C., El-Azhary R.A., Bouwhuis S., Rajkumur S.V. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 48:2003;548-552
20. Urbauer E., Kaufmann H., Nösslinger T., Raderer M., Drach J. Thromboembolic events during treatment with thalidomide. Blood. 99:2002;4247-4248
21. Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., Fassas A., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 100:2002;1168-1171
22. Cavo M., Zamagni E., Cellini C., Tosi P., Cangini D., Cini M., et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 100:2002;2272-2273
23. Osman K., Comenzo R., Rajkumar S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 344:2001;1951-1952